Announcement on Progress of Litigation Involved (II)
Filed with SSE · · 2 pages · Chinese
Summary by 6ix AI
Kangmei Pharmaceutical Co., Ltd has announced the progress of ongoing litigation involving the company, detailing the current status and implications for its financials. The company is currently a respondent in an appeal case where the initial judgment required it to compensate a significant number of investors. The filing highlights that the outcome of the appeal remains uncertain, and the company cannot predict the impact on its profits at this time.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
On 6ix: 6ix.com/news/kangmei-pharmaceutical-co-ltdannouncement-on-progress-of-litigation-involved-ii
Kangmei Pharmaceutical Co., Ltd on 6ix
Earlier from Kangmei Pharmaceutical
- Notice on Convening the 2nd Extraordinary General Meeting in 2026
- Announcement on Progress in Litigation Involved
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
- Announcement on Changing Business Scope and Amending the Articles of Association
- Announcement on Resolutions of the 2025 Annual General Meeting
Later from Kangmei Pharmaceutical
- Announcement on Convening the 2026 Semi-annual Performance Briefing
- Announcement on Resolutions of the 6th Extraordinary Meeting of the 10th Board of Directors in 2026
- (600518)"Kangmei Pharmaceutical Co., Ltd."Announcement on Resolutions of the 8th Extraordinary Meeting of the 10th Board of Directors in 2026
- (600518)"Kangmei Pharmaceutical Co., Ltd."Announcement on Share Repurchase Plan through Call Auction
- (600518)"Kangmei Pharmaceutical Co., Ltd."Announcement on Departure of an Independent Director upon Expiration of Term
Follow Kangmei Pharmaceutical into a list and get an email when it puts out news.
Follow Kangmei Pharmaceutical